Treatment with TNF inhibitors is associated with a twofold increased risk for new-onset psoriasis compared with nonbiologic agents, suggest findings from a Danish cohort study.

Among people with peripheral spondyloarthritis, those who also have psoriasis show different clinical characteristics to those without the skin condition, study findings indicate.

Among PsO patients, the PsO onset age distinguishes two different patterns: early onset psoriasis (0–40 years) and late-onset psoriasis (over 40 years).

History of psoriasis (PSO), either personal or family history, is an important factor in the diagnosis of PsA.

Exposure to tumor necrosis factor inhibitors is associated with a threefold increased risk for developing psoriasis in children with juvenile idiopathic arthritis, US study findings indicate.

Musculoskeletal inflammation and damage is one of several factors that could help predict psoriatic arthritis development among patients with psoriasis, suggest results of a meta-analysis and systematic review.

Authors: Alen Zabotti, Orazio De Lucia, Garifallia Sakellariou, Alberto Batticciotto, Gilberto Cincinelli, Ivan Giovannini, Luca Idolazzi, Gabriella Maioli, Ilaria Tinazzi, Daniel Aletaha, Salvatore De Vita, Antonio Marchesoni, Josef Smolen, Annamaria Iagnocco, Dennis McGonagle & Roberto Cap Abstract Background Agreement on how to identify psoriasis (PsO) patients at risk of developing psoriatic arthritis (PsA) is lacking.

Treatment with biologic DMARDs could reduce the risk for developing psoriatic arthritis among patients with moderate-to-severe chronic plaque psoriasis, suggest findings from a retrospective study.

Integration of clinical and protein biomarker data using a machine-learning approach may help to distinguish patients with psoriatic arthritis from those with psoriasis, suggests research presented at the ACR Convergence 2020 virtual meeting.

Patients with psoriasis who have structural entheseal lesions and cortical bone loss at entheseal segments are at increased risk for progressing to psoriatic arthritis, research suggests.

As with many rheumatic diseases, diagnosis of psoriatic arthritis is often delayed, contributing to poor quality of life and worse long-term outcomes. Vinod Chandran discusses recent developments in screening tools for identifying patients with psoriatic arthritis, and those who are at high risk for developing this disease.

The aims for screening psoriasis patients may be twofold: to identify psoriasis patients who already have PsA; and to identify patients with psoriasis who are at high risk for developing PsA.

Walsh JA et al. J Rheumatol 2018; Advance online publication. doi: 10.3899/jrheum.170244